Projects & Grants




Colorectal cancer molecular-genetic analysis of selected genes
Project IdRRC/04/2012 DT4
Main solverdoc. MUDr. Jana Dvořáčková, Ph.D.
Periodr8/2012 - 9/2013
ProviderProjekty podporované z rozpočtu měst krajských úřadů
Statefinished
AnotationThe main objective of the project is the analysis of mutations in the genes K-ras, BRAF aPIK3CA in patients with colorectal cancer treated with monoclonal antibodies against EGFR. Patients with mCRC with wild-type K-ras oncogene treatment with monoclonal antibodies against the EGFR (cetuximab, panitumumab) have a significantly longer median survival. Recent studies suggest that mutations in K-ras gene are indeed the main and important but not the only predictor for anti-EGFR therapy. Mutations in the K-ras gene can explain only 30-40% of the resistance to treatment with monoclonal antibodies against the EGFR (cetuximab, panitumumab) in patients with mCRC. Current evidence suggests that damage to other proteins in the EGFR signaling pathway, such as mutations in the BRAF protein and deregulation PIK3CA/PTEN pathway can lead to resistance to anti-EGFR therapy.